HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $12

Benzinga · 06/09 12:00
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $30 to $12.